Background Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure.
Introduction
Immunoglobulin A (IgA) nephropathy is the most common form of chronic glomerulonephritis worldwide. Patients typically present in the second or third decade of life with continuous asymptomatic microscopic hematuria interspersed by recurrent episodes of macroscopic hematuria and proteinuria in association with upper respiratory tract or gastrointestinal infections. Some patients present with acute nephritic and/or nephrotic syndrome. The disease may have a slow progressive course, leading to renal failure in up to 40 % of cases. Renal biopsies typically exhibit mesangioproliferative lesions in glomeruli, with mesangial deposits of IgA, C3 and, to a lesser extent, IgG and IgM. More severe lesions develop in progressive cases, including crescent formation, endocapillary proliferation, glomerulosclerosis, as well as interstitial, tubular and vascular affection [1] .
The pathogenesis of IgA nephropathy has yet to be fully elucidated. The IgA1 found in the circulation and deposited in glomerular lesions has been shown to be galactose-deficient, forming immune complexes with IgG or IgA1 [2, 3] . Genome-wide association studies have identified loci in MHC, CFH/CFHR and HORMAD2, as well as in other genes associated with IgA nephropathy [4] . The association with the CFH/CFHR locus may eventually provide insight into the role of complement and the major soluble inhibitor of the alternative pathway, factor H (encoded by CFH), in the pathogenesis of IgA nephropathy. Homozygous deletions of factor Hrelated proteins 3/1 (CFHR3/1) are considered to be protective [4] , while few patients have been found to have a factor H dysfunction or mutation [5] [6] [7] .
Clinical, serological and histopathological studies have demonstrated that complement is activated during IgA nephropathy. In addition to C3 deposits in the mesangium, biopsies show positive labelling for properdin and the membrane attack complex (MAC, C5b-9) [8, 9] as well as some labelling for C4d, mannose-binding lectin, ficolin [10] and C4-binding protein [11] . Properdin and soluble MAC are also elevated in patient urine [12] . C3 levels in serum are usually normal, but degradation products, such as iC3b-C3d, may be elevated, suggesting activation of the alternative pathway [13] . Furthermore, decreased circulatory C3 levels and increased C3 deposition are suggested to be predictors of worse outcome [14] . Complement activation may thus contribute to renal inflammation during progressive IgA nephropathy [15] . Based on these findings, that suggest complement activation in IgA nephropathy, we treated a young patient with severe IgA nephropathy with the anti-C5 antibody eculizumab in an attempt to salvage renal function.
Case report
A previously healthy 16-year-old white male presented in 2012 with a 1-week history of edema, weight gain and fatigue. At admission he had a pulse rate of 83/min, normal peripheral perfusion and respiration and a blood pressure of 142/ 93 mmHg. The plasma creatinine level was mildly elevated at 114 μmol/L (reference value 60-105 μmol/L) and plasma albumin was 19 g/L (reference value 36-48 g/L). Urinalysis revealed microscopic hematuria and proteinuria with a urinary albumin/creatinine ratio of 864 g/mol (normal range <3.8 g/mol). The patient was initially treated with prednisolone 80 mg/day and referred to Skåne University Hospital in Lund for further investigation. Renal biopsy showed a mesangioproliferative pattern with fibrocellular crescents in two of 15 glomeruli. Immunofluorescence showed intense mesangial staining for IgA and C3, and weak IgG and IgM staining. C5b-9 staining was noted in capillary walls. Based on these findings the patient was diagnosed with IgA nephropathy.
The pathological score according to the Oxford classification [1] was M1 S1 E1 T1. Creatinine levels increased to 165 μmol/L, and the patient was treated with intravenous methylprednisolone pulses and high-dose oral prednisolone followed by mycophenolate mofetil and various anti-hypertensive medications (furosemide, felodipine, labetolol) ( Fig. 1 ). An initial improvement in plasma creatinine and albumin was noted during the first 4 months of treatment ( Fig. 1) accompanied by a decrease in edema. However, approximately 5-6 months after the initiation of treatment a slow rise in creatinine was noted as well as increased proteinuria in spite of continuous treatment with prednisolone (25 mg every other day) and mycophenolate mofetil [750 mg twice a day (b.i.d.)]. Losartan (12.5 mg daily initially, later increased to 25 mg b.i.d.) and enalapril (2.5 mg b.i.d.) treatment were initiated but were not beneficial in controlling urinary protein losses. The patient experienced subjective clinical worsening with fatigue and massive edema. The glomerular filtration rate (GFR) measured by iohexol clearance was 40 ml/ min/1.73 m 2 10 months after presentation. A second renal biopsy performed 1 year after treatment initiation showed fibrocellular and fibrous crescents in 80 % of glomeruli, as well as deposits of IgA, C3 [Electronic Supplementary Material (ESM) Fig. 1a-c] and IgG. The pathological score was M1 S1 E1 T2. Staining for deposition of C5b-9 revealed prominent glomerular C5b-9 staining (ESM Fig. 1d) . The GFR showed a marked decrease to 20 ml/min/ 1.73 m 2 . Due to the rapid progression of renal failure and pronounced clinical worsening, a decision was taken to attempt to block renal inflammation with eculizumab. The patient was treated for a total of 3 months with eculizumab, during which time enalapril and mycophenolate mofetil were discontinued as no beneficial effect of these treatments was noted. Eculizumab was initially given once weekly (900 mg) for 4 weeks followed by treatment every other week 200 mg) , following the dose routine for the treatment of atypical hemolytic uremic syndrome (aHUS). Immediately after the initiation of treatment a drop in serum creatinine (from 369 to 300 μmol/L within 6 days, and to 239 μmol/L one month later) and in proteinuria was noted (Fig. 1) . However, when alternate-week treatment was commenced creatinine levels rose once again (to 309 μmol/L). Assuming that the patient's massive proteinuria contributed to urinary loss of eculizumab the treatment schedule was switched to once weekly at half the recommended dose recommended for adults (ie 600 mg/week). The creatinine levels then stabilized, and this regimen was used until treatment was discontinued after 3 months. The results of a quantitative complement function assay (Wielisa assay; Euro Diagnostica, Malmö Sweden) indicated total blockade. Levels of C3 were normal both before and during treatment, with no elevation of C3dg. The patient showed an initial improvement in creatinine, followed by a slow rise back to the initial level. However, the urinary protein losses diminished and remained lower while the clinical situation improved and edema resolved. The GFR at the end of treatment was 19 ml/min/1.73 m 2 . Weekly controls after discontinuation of eculizumab showed that serum creatinine and albumin levels were stable as long as complement function was blocked. The patient was transferred to the adult nephrology unit at this stage. Six weeks after the patient had discontinued eculizumab the complement function had recovered, and 1 week later a pronounced rise in serum creatinine was noted while proteinuria increased (Fig. 1) . A marked daily increase in creatinine was noted and after 3 days a single dose of eculizumab (900 mg) was administered, again leading to an improvement of renal function, albeit at a higher creatinine level. A third renal biopsy performed at the same time showed that 75 % of glomeruli were sclerotic and that two of 20 glomeruli exhibited fibrotic crescents. The pathological score was M1 S1 E1 T1. Deposits of IgA, C3 and IgG were noted (staining for C5b-9 was not performed). At this point a decision was made by the attending physicians to discontinue eculizumab treatment due to advanced renal failure. Four weeks after the single dose of eculizumab a rapid and sharp rise in creatinine was noted and the patient commenced peritoneal dialysis.
Discussion
Complement activation is not considered to be the primary event triggering renal dysfunction in IgA nephropathy. Nonetheless, prominent complement deposition in glomeruli does occur and most likely contributes to extensive renal inflammation with subsequent cell injury. Glomerular complement deposition and urinary MAC have been associated with more severe renal injury [10, 12, 14] . Kiryluk et al. suggested that patients with IgA nephropathy might benefit from treatment with recombinant factor H or anti-C5 antibodies [15] . In this report we describe for the first time a patient with IgA nephropathy treated with anti-C5 antibody. The beneficial effect of this treatment on renal function and clinical improvement lasted as long as the patient was treated with eculizumab. Discontinuation of treatment led to worsening of renal function that was once again impeded by a single dose of eculizumab. It is possible that treatment initiation earlier in the course of disease would have had a more favorable outcome; nevertheless, clinical deterioration was prevented even when treatment was initiated late in the course of disease.
Eculizumab has a half-life of up to 15 days (median 11 days). Thus, a total normalization of complement function can be expected approximately 1 month after discontinuation. In our patient a very rapid deterioration occurred approximately 6-7 weeks after the termination of treatment when complement function had normalized. When eculizumab was readministered, the decrease in renal function was again impeded, suggesting that the rapid progression of renal failure in this patient was mostly due to complement activation. Unlike patients with aHUS, patients with IgA nephropathy may not require total blockade of the terminal complement pathway to prevent progression, suggesting that these patients could possibly be treated with eculizumab at longer intervals than every other week, depending on the degree of proteinuria. We also speculate that complement-related biomarkers, such as circulating C3 degradation products and soluble MAC in the plasma or urine, as well as C5b-9 staining patterns in renal biopsies, may be useful markers for determining which patients will benefit from eculizumab treatment. This remains to be evaluated in other patients.
Eculizumab was used in our patient as a rescue therapy due to a progressive worsening in renal function. It is a very expensive drug and not approved for use in IgA nephropathy. During the short treatment period of 3 months the patient improved both clinically and subjectively. Patients with IgA nephropathy may benefit from complement inhibition when renal function worsens, and this possibility needs to be explored in future clinical studies. The findings from such studies will determine whether complement activation contributes to the pathogenesis of IgA nephropathy and if eculizumab has a potential role in the treatment of this disease. 
